An update from Pacific Biosciences ( (PACB) ) is now available.
On March 24, 2025, Pacific Biosciences announced the appointment of Jim R. Gibson as its new Chief Financial Officer, effective March 31, 2025. Gibson, who has extensive financial leadership experience from companies like Sequoia and GoDaddy, will replace Christian Henry, who has been serving as interim CFO. Gibson’s appointment is expected to bolster PacBio’s financial strategy and operational scale as the company aims for positive cash flows by 2027.
More about Pacific Biosciences
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions. The company focuses on accuracy, quality, and completeness through its HiFi long-read sequencing and SBB® short-read sequencing technologies. PacBio’s products are used in various research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology.
YTD Price Performance: -29.44%
Average Trading Volume: 11,232,374
Technical Sentiment Signal: Strong Buy
Current Market Cap: $378.3M
See more insights into PACB stock on TipRanks’ Stock Analysis page.